The 28-mer chimeric AD-specific peptide vaccine reported in this study is composed of the doubly phosphorylated Tau B cell epitope Tau229-237[pThr231/pSer235] and an immunomodulatory T cell epitope originating from the antigen Ag85B of the Mycobacterium tuberculosis. The gene discussed is MAPT; the disease is Alzheimer disease.